1. SS-31 (Elamipretide), Best for Mitochondrial Health SS-31 is a cell-permeable tetrapeptide (D-Arg-Dmt-Lys-Phe-NH2) that concentrates 1,000 to 5,000-fold in the inner mitochondrial membrane, where it binds cardiolipin to stabilize cristae structure and optimize electron transport chain efficiency. Mechanism. SS-31 reduces electron leak at complexes I and III, lowers mitochondrial reactive oxygen species production, and improves ADP sensitivity through the adenine nucleotide translocator. Unlike conventional antioxidants that scavenge free radicals after formation, SS-31 prevents their generation at the source. Clinical evidence. Elamipretide received FDA accelerated approval in 2025 for improving muscle strength in patients with Barth syndrome, a rare mitochondrial cardiomyopathy. Phase II/III trials are ongoing or completed for primary mitochondrial myopathy (MMPOWER-3), heart failure with reduced ejection fraction (PROGRESS-HF), and age-related macular degeneration (ReCLAIM). In aged mice, SS-31 treatment reversed age-related redox stress and improved exercise tolerance without increasing mitochondrial content, suggesting improved efficiency of existing mitochondria rather than biogenesis. Relevance to aging. Mitochondrial dysfunction is arguably the most consequential hallmark for functional decline. Age-related drops in skeletal muscle mitochondrial function correlate directly with frailty, falls, and loss of independence. SS-31 has the strongest translational evidence of any peptide in this guide.

GHK-Cu, Best for Skin Aging and Collagen GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper chelate found in human plasma, saliva, and urine. Plasma concentrations decline from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60. Mechanism. GHK-Cu activates or suppresses expression of over 4,000 human genes at a threshold of ≥50% mRNA expression change. A broader analysis from the same in vitro Connectivity Map dataset, including any level of change, identified effects on approximately 7,800 genes (~31% of the genome). These two figures reflect different thresholds from the same dataset and should not be conflated as equivalent. Upregulated pathways include collagen synthesis, elastin production, glycosaminoglycan assembly, antioxidant enzyme expression (superoxide dismutase, glutathione), and DNA repair genes. It also stimulates angiogenesis, nerve outgrowth, and dermal fibroblast proliferation. Clinical evidence. In a 12-week controlled trial using thigh skin biopsies (not facial application), GHK-Cu applied topically improved collagen production in 70% of women treated, compared to 50% with vitamin C and 40% with retinoic acid. These results may not directly translate to facial skincare use. A separate double-blind, split-face study of 60 participants aged 40 to 65 demonstrated a 22% increase in skin firmness and a 16% reduction in fine lines over 12 weeks with 0.05% GHK-Cu serum versus placebo. A 2025 clinical trial of 21 women showed a 28% average increase in collagen density after 3 months of daily application, with top responders reaching 51%. Relevance to aging. Skin is the most visible organ of aging, and collagen loss (approximately 1% per year after age 30) drives wrinkle formation, thinning, and impaired wound healing. GHK-Cu addresses this through multiple convergent pathways rather than a single mechanism, which may explain its broad efficacy across skin endpoints. Limitations. Topical penetration limits systemic effects. Clinical improvements in the 15% to 25% range, while statistically significant, remain smaller than those achieved with prescription retinoids or energy-based devices. Injectable GHK-Cu for systemic anti-aging effects lacks clinical trial support.

“PT-141 peptide for sexual arousal” CAGRILINTIDE Origin: Cagrilintide is a synthetic analogue of amylin, a naturally occurring hormone co-secreted with insulin by the pancreas. Amylin plays a crucial role in regulating blood sugar levels, appetite, and satiety after meals. Individuals with metabolic challenges often have impaired amylin function or production, leading to dysregulated hunger cues and difficulty maintaining a healthy weight. Mechanism: Promotes Satiety: Mimics the effects of amylin, signaling the brain to feel fuller for longer and naturally reducing caloric intake. Slows Gastric Emptying: Delays the passage of food through the stomach, contributing to a prolonged feeling of fullness after eating. Regulates Appetite: Impacts appetite centers in the brain, reducing cravings and improving dietary adherence. Stabilizes Blood Sugar Levels: Works synergistically with insulin to smooth out blood sugar fluctuations, lowering the risk of insulin resistance. Enhances GLP-1 Receptor Agonist Effects: Designed to complement GLP-1 receptor agonists like semaglutide or liraglutide, enhancing their ability to regulate glucose metabolism and promote weight loss. Impact: Sustainable Weight Loss: Targets root causes of weight gain, enabling long-term results by addressing hunger regulation and improving metabolic health markers. Improved Glycemic Control: Enhances insulin sensitivity and reduces postprandial blood sugar levels, benefiting individuals with Type 2 diabetes or other metabolic disorders. Appetite Suppression: Offers sustained appetite regulation, helping patients adhere to calorie-restricted diets and manage weight effectively. Synergistic Effects with GLP-1 Therapy: Co-administration with GLP-1 analogs, such as in the CagriSema formulation, has demonstrated enhanced weight loss and glycemic improvement compared to either therapy alone. Dosage & Administration: Subcutaneous Injection: Typically administered at doses of 250 mcg or less weekly, as part of a supervised weight loss or diabetes management program. Dosage may vary based on specific patient needs and response. Combination Therapy: Frequently co-administered with GLP-1 receptor agonists for synergistic metabolic effects. Safety Profile: Cagrilintide has shown a strong safety and tolerability profile in clinical trials. Common side effects are mild and include gastrointestinal discomfort, such as nausea or constipation, particularly during the initiation phase. These effects are generally transient and manageable with dosage adjustments.

Hey everyone, I’m from Ohio and pretty new to peptides and the whole grey market side of things. I joined because I’ve realized I’ve probably been paying way more than I need to, and I’m trying to learn how people find reliable vendors, read COAs, and avoid getting scammed. Still learning a lot, so definitely here to ask questions and hear what’s worked for everyone else. Glad to be here!